[{"id":"7f63c016-67db-4616-848e-c7533e0a9c03","acronym":"","url":"https://clinicaltrials.gov/study/NCT01792050","created_at":"2021-01-17T17:37:30.462Z","updated_at":"2024-07-02T16:36:44.699Z","phase":"Phase 2","brief_title":"Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer","source_id_and_acronym":"NCT01792050","lead_sponsor":"NewLink Genetics Corporation","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • indoximod (NLG8189)"],"overall_status":"Completed","enrollment":" Enrollment 169","initiation":"Initiation: 02/01/2013","start_date":" 02/01/2013","primary_txt":" Primary completion: 07/01/2016","primary_completion_date":" 07/01/2016","study_txt":" Completion: 07/07/2017","study_completion_date":" 07/07/2017","last_update_posted":"2020-05-28"},{"id":"dd33b34c-fa94-48d0-9b99-6201650c2301","acronym":"","url":"https://clinicaltrials.gov/study/NCT01560923","created_at":"2021-01-18T06:36:45.368Z","updated_at":"2024-07-02T16:36:46.704Z","phase":"Phase 2","brief_title":"Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer","source_id_and_acronym":"NCT01560923","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e indoximod (NLG8189) • Provenge (sipuleucel-T)"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 12/12/2018","primary_completion_date":" 12/12/2018","study_txt":" Completion: 12/12/2018","study_completion_date":" 12/12/2018","last_update_posted":"2020-04-03"}]